Citation: Shizuka Takaku, Naoko Niimi, Toshihiko Kadoya, Hideji Yako, Masami Tsukamoto, Kunihiko Sakumi, Yusaku Nakabeppu, Hidenori Horie, Kazunori Sango. Galectin-1 and galectin-3 as key molecules for peripheral nerve degeneration and regeneration[J]. AIMS Molecular Science, 2016, 3(3): 325-337. doi: 10.3934/molsci.2016.3.325
| [1] | Amena W. Smith, Swapan K. Ray, Arabinda Das, Kenkichi Nozaki, Baerbel Rohrer, Naren L. Banik . Calpain inhibition as a possible new therapeutic target in multiple sclerosis. AIMS Molecular Science, 2017, 4(4): 446-462. doi: 10.3934/molsci.2017.4.446 |
| [2] | Tateki Kikuchi . Circular breakdown of neural networks due to loss of deubiquitinating enzyme (UCH-L1) in gracile axonal dystrophy (gad) mouse. AIMS Molecular Science, 2021, 8(4): 311-324. doi: 10.3934/molsci.2021024 |
| [3] | Dimitra Beroukas, Maurice Selhorst, Stuart M. Pitson, Dusan Matusica, Ian L. Gibbins, Michaela Kress, Rainer V. Haberberger . Sphingosine kinase 1 in murine dorsal root ganglia. AIMS Molecular Science, 2015, 1(1): 22-33. doi: 10.3934/molsci.2015.1.22 |
| [4] | Ashok Chakraborty, Anil Diwan . Molecular mechanisms of neurodegenerative disease (NDD). AIMS Molecular Science, 2023, 10(3): 171-185. doi: 10.3934/molsci.2023012 |
| [5] | Mireille Khacho, Ruth S. Slack . Mitochondrial dynamics in neurodegeneration: from cell death to energetic states. AIMS Molecular Science, 2015, 2(2): 161-174. doi: 10.3934/molsci.2015.2.161 |
| [6] | Sandrine Bouchet, Marion Piedfer, Santos Susin, Daniel Dauzonne, Brigitte Bauvois . In vitro activity of some flavonoid derivatives on human leukemic myeloid cells: evidence for aminopeptidase-N (CD13) inhibition, antiproliferative and cell death properties. AIMS Molecular Science, 2016, 3(3): 368-385. doi: 10.3934/molsci.2016.3.368 |
| [7] | Seidu A. Richard, Wu Min, Zhaoliang Su, Hua-Xi Xu . Epochal neuroinflammatory role of high mobility group box 1 in central nervous system diseases. AIMS Molecular Science, 2017, 4(2): 185-218. doi: 10.3934/molsci.2017.2.185 |
| [8] | Jin Hwan Do . Genome-wide transcriptional comparison of MPP+ treated human neuroblastoma cells with the state space model. AIMS Molecular Science, 2015, 2(4): 440-460. doi: 10.3934/molsci.2015.4.440 |
| [9] | Vahid Pouresmaeil, Marwa Mawlood Salman Al-zand, Aida Pouresmaeil, Seyedeh Samira Saghravanian, Masoud Homayouni Tabrizi . Loading diltiazem onto surface-modified nanostructured lipid carriers to evaluate its apoptotic, cytotoxic, and inflammatory effects on human breast cancer cells. AIMS Molecular Science, 2024, 11(3): 231-250. doi: 10.3934/molsci.2024014 |
| [10] | Jade Sternberg, Miriam Wankell, V. Nathan Subramaniam, Lionel W. Hebbard . The functional roles of T-cadherin in mammalian biology. AIMS Molecular Science, 2017, 4(1): 62-81. doi: 10.3934/molsci.2017.1.62 |
Galectins, a family of b-galactoside-binding animal lectins, are involved in a wide variety of physiological and pathological processes [1]. We’ve been focusing on two major galectins, galectin-1 (GAL-1) and galectin-3 (GAL-3), as modulators of axonal degeneration and regeneration in the peripheral nervous system (PNS) [2,3,4]. Galectins have homologous carbohydrate-recognition domains (CRDs) with about 130 amino acids; while GAL-1 has one CRD domain and exists as a monomer as well as a non-covalent homodimer, GAL-3 has chimeric structure with a N-terminal non-lectin domain associated with a C-terminal CRD [1]. Despite lacking a classical signaling sequence to enter the endoplasmic reticulum, both GAL-1 and GAL-3 are subject to externalization from various kinds of cells by a non-classical secretory pathway [5]. Following externalization, some of the galectin molecules are suggested to associate with surface or extracellular matrix glycoconjugates where lectin activity is stabilized, while the others free from glycoconjugate ligands are rapidly oxidized in the non-reducing extracellular environment [6]. Contrary to the concept that galectins are biologically active only in the reduced form, we introduced the oxidized form of GAL-1 (GAL-1/Ox) as a novel factor to promote axonal regeneration in the PNS [7]. Most of the studies on the bioactivities of GAL-1 were carried out under reducing conditions; however, GAL-1/Ox containing three intramolecular disulfide bonds lacks lectin activity and acts on the nervous tissue as a cytokine-like molecule [8]. Further studies have indicated that both reduced and oxidized forms of GAL-1 play important roles in axonal degeneration and regeneration in the PNS [9,10,11]. GAL-3 has also been considered as a key molecule in the neural functions [12,13]; unlike GAL-1, GAL-3 containing only one Cysteine residue in the molecule is unable to form disulfide bonds under oxidative conditions, thus it exists only as a lectin [9].
The aim of this paper is to summarize the recent progress in the research of distribution and function of GAL-1 and GAL-3 in the PNS at mature stages. We also introduce our new findings for the better understanding of possible roles of these molecules in the process of axonal regeneration and the pathogenesis of peripheral neuropathies.
GAL-1 and GAL-3 are highly expressed in peripheral nervous tissues of adult rodents, with immunoreactivity localized to cell bodies of sensory neurons, axons and Schwann cells [2,3,14,15]. The immunoreactivity for GAL-1, but not GAL-3, has been detected in spinal motoneurons [14]. Little is known about the distribution of these lectins in the autonomic nervous system; GAL-1 mRNA is not detected in sympathetic neurons of superior cervical ganglia or parasympathetic neurons of sphenopalatine ganglia [16], whereas GAL-3 immunoreactivity is found in the autonomic preganglionic neurons in the spinal cord [17].
Primary sensory neurons in dorsal root ganglia (DRG) transmit various kinds of somatosensory information from the periphery to the central nervous system (CNS). The small diameter DRG neurons possessing small myelinated and unmyelinated fibers can play an essential role in nociception and thermoreception, whereas the large diameter neurons possessing large myelinated fibers are known to be mostly sensitive mechanoreceptors [18]. Predominant expression of GAL-1 and GAL-3 in subpopulations of small DRG neurons (Figure 1) suggests that these molecules are involved in the small fiber functions [2,3,14,16,19]. Consistent with these distribution patterns, mice lacking GAL-1 showed reduced sensitivity to noxious thermal stimuli [20]. Similarly, mice deficient in GAL-3 markedly reduced herpes zoster-associated pain [21]; however, the authors in that study attributed the herpetic pain to GAL-3 expressed in macrophages/microglia in the spinal cord, rather than that expressed in DRG neurons. It should also be added that adult DRG neurons are classified into three principal subgroups by their cell size and characteristic markers; large neurons (immunoreactive for 200 kD neurofilaments), small peptidergic neurons (immunoreactive for calcitonin gene-related peptide, substance P (SP) and high-affinity nerve growth factor (NGF) receptor TrkA), and small non-peptidergic neurons (immunoreactive for glial cell line-derived neurotrophic factor (GDNF) receptors RET and GFRa and binding to isolectin B4 (IB4)) [2,22]. Whether these two groups of small neurons have distinct functions has been the subject of controversy [23]. It is generally accepted that GAL-1 mRNA/protein is predominantly expressed in small non-peptidergic neurons (Figure 2) [2,24]. Although precise distribution of GAL-3 in DRG remains unclear, our recent study revealed predominant expression of GAL-3 in small IB4-binding DRG neurons with a considerable co-localization with GAL-1 [3].
Figure 1. Immunohistochemical localization of GAL-1 and GAL-3 in the sections of adult rat DRG. The immunoreaction was visualized using 0.01% diaminobenzidine tetrahydro-chloride and 0.01% hydrogen chloride. The small neuron-dominant expression patterns of these galectins suggest their functional roles in nociception and thermoreception [2,3,14,16,19]The expression of GAL-1 mRNA/protein in DRG neurons was found to be up-regulated by peripheral nerve injury. Medium- to large-sized DRG neurons, which have weak GAL-1-immunoreactivity when uninjured, were found to increase the immunoreactivity 1-2 weeks after sciatic nerve axotomy [25]. GAL-1 mRNA/protein in spinal motoneurons similarly increased 7 and 14 days after spinal nerve axotomy [26]. These findings suggest that axtomy can trigger the synthesis of GAL-1 in cell bodies of DRG neurons and motoneurons. GAL-1 up-regulated in neuronal cell bodies may be transported to a damaged region and secreted [9,19]. We failed to find papers that described the expression of GAL-3 in DRG neurons or motoneurons after axotomy. However, GAL-3 (aka MAC-2) up-regulated in Schwann cells and macrophages after peripheral nerve injury may play a role in phagocytosis during Wallerian degeneration [27,28].
Figure 2. Immunofluorescence micrographs of adult rat DRG sections, stained with antibodies to GAL-1 (red) and CGRP, IB4, or NF200 (green). The merged pictures are on the right. GAL-1 is predominantly expressed in IB4-binding small non-peptidergic neurons [2,24] (reproduced from Sango et al., Basic Principles of Peripheral Nerve Disorders 2012 [2])Intense GAL-1 immunoreactivity was detected in almost all DRG neurons in culture (Figure 3). Enzymatic and mechanical dissociation of DRGs to isolate neurons from non-neuronal cells can be a more potent inducer for the synthesis of GAL-1 than axotomy in vivo [19]. In contrast, we observed predominant expression of GAL-3 in small DRG neurons in vitro as well as in vivo (Figure 3). Double immunofluorescent staining showed a tendency that GAL-3 was co-localized with non-peptidergic neuron markers IB4 and P2X3 purinoreceptor [29], but not with a peptidergic neuron marker SP (Figure 4). These findings suggest that the small non-peptidergic neuron-predominant expression pattern of GAL-3 is persistent after in vivo/in vitro replacement.
Figure 3. Immunohistochemical localization of GAL-1 (red) and GAL-3 (green) in adult rat DRG neurons after 2 days in culture. GAL-1 is distributed to almost all neurons [19], whereas GAL-3 is predominantly expressed in small neurons
Figure 4. Immunohistochemical localization of GAL-3 (green) and substance P (SP), IB4, or P2X3 (red) in adult rat DRG neurons after 2 days in culture. SP is a peptidergic neuron marker [23], whereas IB4 and P2X3 are non-peptidergic neuron markers [29]. The pictures indicate that GAL-3 is predominantly expressed in non-peptidergic neuronsBecause GDNF is likely to exert its major effects on small non-peptidergic neurons through RET and GFRa1 receptors [23,30], it seems plausible that synthesis and/or distribution of GAL-1 and GAL-3 in these neurons can be modulated by GDNF. We observed that recombinant GDNF applied to culture medium enhanced neurite outgrowth as well as protein expression of GAL-1 and GAL-3 in cultured adult rat DRG cells [3]. These findings suggest that both GAL-1 and GAL-3 are downstream target molecules for the GDNF signaling in DRG neurons. The possible functional roles of these galectins in GDNF-induced neurite outgrowth will be discussed in the 3rd section.
Both GAL-1 and GAL-3 are expressed in primary cultured Schwann cells, as well as immortalized adult rodent Schwann cells IMS32 and IFRS1 [3,4,19,31]. In contrast to DRG neurons, treatment with GDNF failed to up-regulate GAL-1 expression in IFRS1 cells [3], which implies that GDNF/GAL-1 signaling axis is more associated with neurite outgrowth from DRG neurons, rather than Schwann cell migration and myelination. Exposure to high glucose (30 mM) and 3-deoxyglucosone (3-DG), a precursor of advanced glycation endproducts (AGEs), significantly up-regulated GAL-3 expression in IFRS1 cells [4]. The high glucose-induced up-regulation of GAL-3 was abolished by co-treatment with an anti-glycated agent aminoguanidine or an anti-oxidant trans-resveratrol. These findings suggest the involvement of GAL-3 in the pathogenesis of diabetic neuropathy, such as glycation and oxidative stress. The roles of GAL-3 in Schwann cells under diabetic conditions will be described in the 4th section.
Successful nerve regeneration with functional repair in the PNS can be attributed to both intrinsic and extrinsic factors, such as the ability of neurons to regenerate axons, the distal environment supportive of axonal growth, and the target tissues receptive to re-innervation [32]. The growing evidence suggest that both GAL-1 and GAL-3 are involved in the process of Wallerian degeneration distal to the injury and subsequent axonal regrowth and functional re-innervation [13]; both reduced and oxidized forms of GAL-1 have been shown to promote axonal regeneration in vivo and in vitro, whereas GAL-3 appears to be a key molecule in phagocytosis during Wallerian degeneration, as described above.
When used as a coating substratum, recombinant reduced GAL-1 promoted adhesion and neurite fasciculation of newborn rat DRG neurons [33] and olfactory neurons in culture [34,35]. In contrast, however, we saw no significant effects of GAL-1 on attachment or neurite extension of adult rat DRG neurons [3]. Plachta et al. [11] identified GAL-1 in the reduced form as an inducible factor for the degeneration of neuronal processes growing from embryonic stem cell-derived neurons. They also observed a delay in the process of elimination of peripheral nerve endings after sciatic nerve injury in GAL-1 deficient mice. These finding suggest that GAL-1 is a key molecule for the normal onset of Wallerian degeneration.
The bioactivity of recombinant GAL-1/Ox was extensively evaluated both in vivo and invitro [2,7,8,9,15]. GAL-1/Ox dose-dependently (pg/mL range) increased the number and length of neurites emerging from transected nerve terminals of DRG explants embedded in collagen gel. A similarly low concentration of recombinant GAL-1/Ox also promoted the elongation rate of regenerating axons with migrating Schwann cells after peripheral nerve transection and crush in vivo. In contrast, treatment with recombinant GAL-3, which has a typical lectin activity under non-reducing conditions, failed to enhance axonal regeneration either in the in vitro or in vivo experiments [7]. Moreover, a GAL-1 mutant CSGAL-1, in which all six cysteine residues were replaced by serine, possessed the lectin activity even under non-reducing conditions but lacked the neurite outgrowth-promoting activity [8]. These findings suggest that the lectin properties are not involved in the function of GAL-1/Ox as a stimulant of axonal regeneration. A N-terminally processed from of GAL-1 (GAL-1b) exists as a monomer regardless of redox conditions, and displayed the neurite outgrowth-promoting activity equivalent to the full-length form of GAL-1/Ox [36]. Unlike the neurotrophic factors such as NGF and GDNF, recombinant GAL-1/Ox failed to enhance neurite outgrowth from isolated DRG neurons [2,3]. Although the receptors that specifically recognize GAL-1/Ox have not been identified, it is more likely that GAL-1/Ox stimulates non-neuronal cells to promote axonal regeneration rather than directly acts on neurons. Subsequent analyses by others and us have indicated that macrophages can be a target cell of GAL-1/Ox [37,38,39,40,41]. On the basis of these findings, we have proposed a possible action mechanism of GAL-1/Ox as follows; 1) GAL-1 in the reduced form is released from neurons and Schwann cells upon axonal injury, 2) some of GAL-1 molecule is converted to GAL-1/Ox in the extracellular space, and 3) GAL-1/Ox stimulates macrophages to secrete some neurotrophic molecules, which in turn enhances neurite regeneration and Schwann cell migration.
In normal mice, the axotomy-induced accumulation of macrophages in sciatic nerve distal to ligation was inhibited by injection of anti-GAL-1 antibody. In contrast, injection of GAL-1/Ox into uninjured sciatic nerve promoted the accumulation of macrophages. In agreement with these findings, GAL-1 deficient mice displayed delayed and diminished macrophage accumulation by sciatic nerve injury [40]. These findings suggest the involvement of GAL-1/Ox, as well as GAL-1 in the reduced from [11], in the prompt response of macrophages to axonal injury, which is essential for the normal onset of Wallerian degeneration.
As mentioned above, we failed to observe the significant bioactivity of recombinant GAL-3 on axonal regeneration in vivo (nerve transection/crush models) or in vitro (neurite elongation from DRG explants) [7]. However, the endogenous function of GAL-3 in the PNS after injury is well characterized by the striking phenotypes displayed by the genetic manipulation in mice [13,42,43]. Narcico et al. [42] reported that GAL-3 deficient mice displayed faster axonal regeneration with earlier functional recovery after sciatic nerve crush than their wild-type littermates. The following study by the same group [43] revealed enhanced phagocytic potential of macrophages and Schwann cells in GAL-3 deficient mice than wild-type mice. They also observed more robust up-regulation of RNA/protein expression of the pro-inflammatory cytokines IL-1β and TNF-α, as well as Toll-like receptor-2 and -4, in injured nerves from GAL-3 deficient mice than those from WT mice. These findings suggest that the absence of GAL-3 augments the inflammatory responses and the phagocytic activity of macrophages and Schwann cells after axonal injury, thereby being a cause of the acceleration in the process of Wallerian degeneration. Although these studies have shed light on the pathological roles of GAL-3 in axonal regeneration, it is controversial whether GAL-3 inhibits the function of macrophages and Schwann cells after injury or disease in the PNS [3,4,12,13,27,28,44,45].
Predominant expression of GAL-1 and GAL-3 in GDNF-responsive small non-peptidergic DRG neurons as described above led us to speculate that these lectins might be involved in the signaling pathways in GDNF-induced neurite outgrowth [46]. In our study [3], treatment of cultured DRG neurons with recombinant GDNF significantly increased the neurite length, as well as the population of IB4-binding neurons and the protein expression of GAL-1. The GDNF-induced DRG neurite outgrowth and GAL-1 up-regulation were abolished by anti-RET antibody and phosphatidyl inositol-3’-phosphate-kinase (PI3K) inhibitor LY294002. These findings suggest that the neurite-outgrowth promoting activity of GDNF may be attributable, at least partly, to the up-regulation of GAL-1 through RET-PI3K pathway. However, we observed no significant differences between GAL-1 deficient mice and wild-type mice in DRG neurite outgrowth in the presence or absence of GDNF. Some studies imply functional redundancies between GAL-1 and other lectin molecules, including GAL-3 [47]. Considerable colocalization of GAL-3 with GAL-1 in DRG sections and GDNF-induced up-regulation of GAL-3 as well as GAL-1 in DRG cultures suggest that the both galectins are downstream target molecules for the GDNF signaling in DRG neurons. In addition, recombinant GAL-3 used as a coating substratum slightly but significantly promoted neurite outgrowth from cultured DRG neurons, whereas recombinant GAL-1 had no significant effects. Although further analyses such as the selective knock down of GAL-3 and double knock down of GAL-1 and GAL-3 are required, it seems reasonable to suppose that GAL-3 might play a more crucial role than GAL-1 and/or compensate for GAL-1 deficiency in GDNF-induced neurite outgrowth.
Metabolic disorders due to hyperglycemia, such as increased flux of the polyol and hexosamine pathways, formation of AGEs, alteration of protein kinase C activities, and increased oxidative stress, are believed to play a major role in the development and progression of diabetic neuropathy [48]. There is sufficient evidence to show that Schwann cells are highly vulnerable to these disorders [49], and IMS32 and IFRS1 cells have been utilized as useful tools for the study of diabetic neuropathy [31]. GAL-3 is recognized as an AGE-binding protein, but its significance in the pathogenesis of diabetic complications remains unclear [50]. As described above, we observed the up-regulation of GAL-3 in IFRS1 cells under diabetic conditions. In addition, recombinant GAL-3 applied to culture medium resulted in the significant up-regulation of an anti-apoptotic marker Bcl-2 and the downregulation of an oxidative stress marker 4-hydroxynonenal [4]. Furthermore, knockdown of GAL-3 expression in IFRS1 cells by RNA interference resulted in the impaired cell viability after 7 days exposure to 3-DG (Niimi et al., unpublished data). These findings suggest cytoprotective properties of GAL-3 in Schwann cells under diabetic conditions. In agreement with our studies, GAL-3 deficient mice rendered diabetic by streptozotocin displayed more severe nephropathy with increased accumulation of renal glomerular AGEs than their normal littermates [51]. GAL-3 may play a role in the prevention of diabetic complications by removing the increased amounts of AGEs, but further evidence is needed to support this idea.
So far, no papers have documented the involvement of GAL-1 in the pathogenesis of diabetic neuropathy. However, recent studies have implicated GAL-1 as an angiogenic factor associated with proliferative diabetic retinopathy [52] and as a marker protein for the progression of diabetic nephropathy [53]. Our ongoing studies to establish immortalized Schwann cells from GAL-1 deficient mice will be helpful to indicate possible roles of GAL-1 in diabetic neuropathy.
Contrary to our expectations, surprisingly few studies have so far been made at the implications of GAL-1 and GAL-3 in peripheral neuropathies other than diabetic neuropathy. Giant axonal neuropathy (GAN) is hereditary neurodegenerative disease affecting both the CNS and PNS, and characterized by aggregates of intermediate filaments in different tissues. Proteomic analysis in cultured fibroblasts from patients with GAN and age- and gender-matched healthy people revealed the up-regulation of GAL-1 in the GAN samples [54]. Because GAL-1 plays a role in cytoskeletal regulation [10], its dysregulation might be involved in the formation of aggregates of intermediate filaments. Several studies have indicated the roles of GAL-1 and GAL-3 in regulation of myelination in the CNS and their involvement in demyelinating disorders such as multiple sclerosis [13,45,55]; however, little is known about their participation in demyelinating neuropathies [56].
We summarized the progress of research for nearly 3 decades on the distribution and function of GAL-1 and GAL-3 in the PNS. Although there is room for further investigation, it is no doubt that both galectins are key molecules for peripheral nerve degeneration and regeneration. The future direction of the research in this field will be to develop novel strategies for functional restoration after peripheral nerve injury and therapeutic efficacy against diabetic and other neuropathies. One of the critical issues for the therapeutic applications of GAL-1 and GAL-3 is establishing the effective systems to deliver these molecules toward the pathologically relevant sites [57]. Although our previous approaches for the therapeutic use of GAL-1/Ox against peripheral nerve injury [58] were unsuccessful, the progress of research on characterization of human GAL-1/Ox [59,60] would pave the way for its exploitation as a pharmaceutical product. In addition, recent studies indicate the beneficial effects of GAL-1 on wound healing [61] and GAL-3 against diabetes and other metabolic disorders [62], which may also be applicable to the prevention and treatment of diabetic neuropathy.
Our work reported in this review was supported by Grants-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (grant number: 25430056 and 16K07048) and the fund from the Nukada Institute for Medical and Biological Research, Chiba, Japan, and was partly performed in the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University. We thank Drs. Kazunori Utsunomiya, Kazuhiko Watabe, Soroku Yagihashi and Hitoshi Nukada for helpful suggestions, and Emiko Kawakami, Hiroko Yanagisawa, and the late Kyoko Ajiki for technical help.
All authors declare no conflict of interest in this paper.
| [1] |
Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10: e17. doi: 10.1017/S1462399408000719
|
| [2] | Sango K, Yanagisawa H, Watabe K, et al. (2012) Chapter 3: Galectin-1 as a multifunctional molecule in the peripheral nervous system after injury, In: Rayegani, S.M. Editor, Basic Principles of Peripheral Nerve Disorders, Rijeka, InTech d.o.o., 31-46. |
| [3] |
Takaku S, Yanagisawa H, Watabe K, et al. (2013) GDNF promotes neurite outgrowth and upregulates galectin-1 through the RET/PI3K signaling in cultured adult rat dorsal root ganglion neurons. Neurochem Int 62: 330-339. doi: 10.1016/j.neuint.2013.01.008
|
| [4] |
Tsukamoto M, Sango K, Niimi N, et al. (2015) Upregulation of galectin-3 in immortalized Schwann cells IFRS1 under diabetic conditions. Neurosci Res 92: 80-85. doi: 10.1016/j.neures.2014.11.008
|
| [5] |
Delacour D, Koch A, Jacob R (2009) The role of galectins in protein trafficking. Traffic 10: 1405-1413 doi: 10.1111/j.1600-0854.2009.00960.x
|
| [6] | Tracey BM, Feizi T, Abbott WM, et al. (1992) Subunit molecular mass assignment of 14,654 Da to the soluble beta-galactoside-binding lectin from bovine heart muscle and demonstration of intramolecular disulfide bonding associated with oxidative inactivation. J Biol Chem 267: 10342-10347. |
| [7] | Horie H, Inagaki Y, Sohma Y, et al. (1999) Galectin-1 regulates initial axonal growth in peripheral nerves after axotomy. J Neurosci 19: 9964-9974. |
| [8] |
Inagaki Y, Sohma Y, Horie H, et al. (2000) Oxidized galectin-1 promotes axonal regeneration in peripheral nerves but does not possess lectin properties. Eur J Biochem 267: 2955-2964. doi: 10.1046/j.1432-1033.2000.01311.x
|
| [9] |
Kadoya T, Horie H (2005) Structural and functional studies of galectin-1: a novel axonal regeneration-promoting activity for oxidized galectin-1. Curr Drug Targets 6: 375-383. doi: 10.2174/1389450054022007
|
| [10] | Camby I, Le Mercier M, Lefranc F, et al. (2006) Galectin-1: a small protein with major functions. Glycobiology 16: 137R-157R. |
| [11] |
Plachta N, Annaheim C, Bissière S, et al. (2007) Identification of a lectin causing the degeneration of neuronal processes using engineered embryonic stem cells. Nature Neurosci 10: 712-719. doi: 10.1038/nn1897
|
| [12] | Pesheva P, Kuklinski S, Schmitz B, et al. (1998) Galectin-3 promotes neural cell adhesion and neurite growth. J Neurosci Res 154: 639-654. |
| [13] | Chen H-L, Liao F, Lin T-N, et al. (2014) Chapter 24: Galectins and neuroinflammation, In: Yu, R.K. & Schengrund C.-L. Editors, Glycobiology of the Nervous System, Advances in Neurobiology 9, New York, Springer Science+Business Media, 517-542. |
| [14] |
Regan LJ, Dodd J, Barondes SH, et al. (1986) Selective expression of endogenous lactose-binding lectins and lactoseries glycoconjugates in subsets of rat sensory neurons. Proc Natl Acad Sci U S A 83: 2248-2252. doi: 10.1073/pnas.83.7.2248
|
| [15] | Fukaya K, Hasegawa M, Mashitani T, et al. (2003) Oxidized galectin-1 stimulates the migration of Schwann cells from both proximal and distal stumps of transected nerves and promotes axonal regeneration after peripheral nerve injury. J Neuropathol Exp Neurol 62: 162-172. |
| [16] |
Akazawa C, Nakamura Y, Sango K, et al. (2004) Distribution of the galectin-1 mRNA in the rat nervous system: its transient upregulation in rat facial motor neurons after facial nerve axotomy. Neuroscience 125: 171-178. doi: 10.1016/j.neuroscience.2004.01.034
|
| [17] | Park MJ, Chung K (1999) Endogenous lectin (RL-29) expression of the autonomic preganglionic neurons in the rat spinal cord. Anat Rec 254: 53-60. |
| [18] |
Salt TE, Hill RG (1983) Neurotransmitter candidates of somatosensory primary afferent fibers. Neuroscience 10: 1083-1103. doi: 10.1016/0306-4522(83)90101-X
|
| [19] |
Sango K, Tokashiki A, Ajiki K, et al. (2004) Synthesis, localization and externalization of galectin-1 in mature dorsal root ganglion neurons and Schwann cells. Eur J Neurosci 19: 55-64. doi: 10.1046/j.1460-9568.2003.03102.x
|
| [20] |
McGraw J, Gaudet AD, Oschipok LW, et al. (2005) Altered primary afferent anatomy and reduced thermal sensitivity in mice lacking galectin-1. Pain 114: 7-18. doi: 10.1016/j.pain.2004.10.009
|
| [21] |
Takasaki I, Taniguchi K, Komatsu F, et al. (2012) Contribution of spinal galectin-3 to acute herpetic allodynia in mice. Pain 153: 585-592. doi: 10.1016/j.pain.2011.11.022
|
| [22] |
Molliver DC, Wright DE, Leitner ML, et al. (1997) IB4-binding DRG neurons switch from NGF to GDNF dependence in early postnatal life. Neuron 19: 849-861. doi: 10.1016/S0896-6273(00)80966-6
|
| [23] |
Ernsberger U (2009) Role of neurotrophin signalling in the differentiation of neurons from dorsal root ganglia and sympathetic ganglia. Cell Tissue Res 336: 349-384. doi: 10.1007/s00441-009-0784-z
|
| [24] |
Imbe H, Okamoto K, Kadoya T, et al. (2003) Galectin-1 is involved in the potentiation of neuropathic pain in the dorsal horn. Brain Res 993: 72-83. doi: 10.1016/j.brainres.2003.08.064
|
| [25] |
McGraw J, Gaudet AD, Oschipok LW, et al. (2005) Regulation of neuronal and glial galectin-1 expression by peripheral and central axotomy of rat primary afferent neurons. Exp Neurol 195: 103-114. doi: 10.1016/j.expneurol.2005.04.004
|
| [26] |
McGraw J, Oschipok LW, Liu J, et al. (2004) Galectin-1 expression correlates with the regenerative potential of rubrospinal and spinal motoneurons. Neuroscience 128: 713-719. doi: 10.1016/j.neuroscience.2004.06.075
|
| [27] | Reichert F, Saada A, Rotshenker S (1994) Peripheral nerve injury induces Schwann cells to express two macrophage phenotypes: phagocytosis and the galactose-specific lectin MAC-2. J Neurosci 14: 3231-3245. |
| [28] | Mietto BS, Mostacada K, Martinez AM (2015) Neurotrauma and inflammation: CNS and PNS responses. Mediat Inflamm 2015: 251204. |
| [29] |
Dussor G, Koerber HR, Oaklander AL, et al. (2009) Nucleotide signaling and cutaneous mechanisms of pain transduction. Brain Res Rev 60: 24-35. doi: 10.1016/j.brainresrev.2008.12.013
|
| [30] |
Carmillo P, Dagø L, Day ES, et al. (2005) Glial cell line-derived neurotrophic factor (GDNF) receptor a-1 (GFR a1) is highly selective for GDNF versus artemin. Biochemistry 44: 2545-2554. doi: 10.1021/bi049247p
|
| [31] | Sango K, Yanagisawa H, Takaku S, et al. (2011) Immortalized adult rodent Schwann cells as in vitro models to study diabetic neuropathy. Exp Diabetes Res 2011:374943. |
| [32] |
Scheib J, Höke A (2013) Advances in peripheral nerve regeneration. Nat Rev Neurol 9: 668-676. doi: 10.1038/nrneurol.2013.227
|
| [33] |
Outenreath RL, Jones AL (1992) Influence of an endogenous lectin substrate on cultured dorsal root ganglion cells. J Neurocytol 21: 788-795. doi: 10.1007/BF01237904
|
| [34] | Mahanthappa NK, Cooper DN, Barondes SH, et al. (1994) Rat olfactory neurons can utilize the endogenous lectin, L-14, in a novel adhesion mechanism. Development 120: 1373-1384. |
| [35] |
Puche AC, Poirier F, Hair M, et al. (1996) Role of galectin-1 in the developing mouse olfactory system. Dev Biol 179: 274-287. doi: 10.1006/dbio.1996.0257
|
| [36] |
Miura T, Takahashi M, Horie H, et al. (2004) Galectin-1b, a natural monomeric form of galectin-1 lacking its six amino-terminal residues promotes axonal regeneration but not cell death. Cell Death Differ 11: 1076-1083. doi: 10.1038/sj.cdd.4401462
|
| [37] | Horie H, Kadoya T, Hikawa N, et al. (2004) Oxidized galectin-1 stimulates macrophages to promote axonal regeneration in peripheral nerves after axotomy. J Neurosci 24: 1873-1880. |
| [38] | Echigo Y, Sugiki H, Koizumi Y, et al. (2010) Activation of RAW264.7 macrophages by oxidized galectin-1. Immunol Lett 131: 19-23. |
| [39] | Kogawa Y, Nakajima K, Sasaguri K, et al. (2011) Oxidized galectin-1 reduces lipopolysaccharide-induced increase of proinflammatory cytokine mRNA in cultured macrophages. Clin Cosmet Investig Dent 19: 1-8. |
| [40] |
Gaudet AD, Leung M, Poirier F, et al. (2009) A role for galectin-1 in the immune response to peripheral nerve injury. Exp Neurol 220: 320-327. doi: 10.1016/j.expneurol.2009.09.007
|
| [41] |
Gaudet AD, Sweet DR, Polinski NK, et al. (2015) Galectin-1 in injured rat spinal cord: implications for macrophage phagocytosis and neural repair. Mol Cell Neurosci 64: 84-94. doi: 10.1016/j.mcn.2014.12.006
|
| [42] |
Narciso MS, Mietto Bde S, Marques SA, et al. (2009) Sciatic nerve regeneration is accelerated in galectin-3 knockout mice. Exp Neurol 217: 7-15. doi: 10.1016/j.expneurol.2009.01.008
|
| [43] |
Mietto BS, Jurgensen S, Alves L, et al. (2013) Lack of galectin-3 speeds Wallerian degeneration by altering TLR and pro-inflammatory cytokine expressions in injured sciatic nerve. Eur J Neurosci 37: 1682-1690. doi: 10.1111/ejn.12161
|
| [44] |
Rotshenker S (2009) The role of Galectin-3/MAC-2 in the activation of the innate-immune function of phagocytosis in microglia in injury and disease. J Mol Neurosci 39: 99-103. doi: 10.1007/s12031-009-9186-7
|
| [45] |
Gustavsson P, Linsmeier CE, Leffler H, et al. (2007) Galectin-3 inhibits Schwann cell proliferation in cultured sciatic nerve. Neuroreport 18: 669-673. doi: 10.1097/WNR.0b013e3280bef97b
|
| [46] |
Tucker BA, Rahimtula M, Mearow KM (2006) Laminin and growth factor receptor activation stimulates differential growth responses in subpopulations of adult DRG neurons. Eur J Neurosci 24: 676-690. doi: 10.1111/j.1460-9568.2006.04963.x
|
| [47] | Wang W, Park JW, Wang JL, et al. (2006) Immunoprecipitation of spliceosomal RNAs by antisera to galectin-1 and galectin-3. Nucleic Acids Res 34: 5166-5174. |
| [48] |
Yagihashi S, Mizukami H, Sugimoto K (2011) Mechanism of diabetic neuropathy: Where are we now and where to go? J Diabetes Investig 2: 18-32. doi: 10.1111/j.2040-1124.2010.00070.x
|
| [49] |
Mizisin AP (2014) Mechanisms of diabetic neuropathy: Schwann cells. Handb Clin Neurol 126: 401-428. doi: 10.1016/B978-0-444-53480-4.00029-1
|
| [50] | Pugliese G, Iacobini C, Pesce CM, et al. (2015) Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology 25: 136-150. |
| [51] | Pugliese G, Pricci F, Iacobini C, et al. (2001) Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J 15: 2471-2479. |
| [52] |
Kanda A, Noda K, Saito W, et al. (2015) Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Sci Rep 5: 17946. doi: 10.1038/srep17946
|
| [53] |
Liu Y, Long L, Yuan F, et al. (2015) High glucose-induced Galectin-1 in human podocytes implicates the involvement of Galectin-1 in diabetic nephropathy. Cell Biol Int 39: 217-223. doi: 10.1002/cbin.10363
|
| [54] |
Mussche S, De Paepe B, Smet J, et al. (2012) Proteomic analysis in giant axonal neuropathy: new insights into disease mechanisms. Muscle Nerve 46: 246-256. doi: 10.1002/mus.23306
|
| [55] |
Franco PG, Pasquini LA, Pérez MJ, et al. (2015) Paving the way for adequate myelination: The contribution of galectin-3, transferrin and iron. FEBS Lett 589: 3388-3395. doi: 10.1016/j.febslet.2015.08.001
|
| [56] | Peng W (2012) Intravenous immunoglobulin treatment on anti-GM1 antibodies associated neuropathies inhibits cholera toxin and galectin-1 binding to ganglioside GM1. Immunol Lett 143: 146-151. |
| [57] | Bojarová P, Křen V (2016) Sugared biomaterial binding lectins: achievements and perspectives. Biomater Sci in press. |
| [58] |
Kadoya T, Oyanagi K, Kawakami E, et al. (2005) Oxidized galectin-1 advances the functional recovery after peripheral nerve injury. Neurosci Lett 380: 284-288. doi: 10.1016/j.neulet.2005.01.054
|
| [59] | Scott SA, Bugarcic A, Blanchard H (2009) Characterisation of oxidized recombinant human galectin-1. Protein Pept Lett 16: 1249-1255. |
| [60] | Guardia CM, Caramelo JJ, Trujillo M, et al. (2014) Structural basis of redox-dependent modulation of galectin-1 dynamics and function. Glycobiology 24: 428-441. |
| [61] |
Lin YT, Chen JS, Wu MH, et al. (2015) Galectin-1 accelerates wound healing by regulating the neuropilin-1/Smad3/NOX4 pathway and ROS production in myofibroblasts. J Invest Dermatol 135: 258-268. doi: 10.1038/jid.2014.288
|
| [62] | Pugliese G, Iacobini C, Pesce CM, et al. (2015) Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology 25: 136-150. |
| 1. | João Ronielly Campêlo Araújo, Cauê Barbosa Coelho, Adriana Rolim Campos, Renato de Azevedo Moreira, Ana Cristina de Oliveira Monteiro-Moreira, Animal Galectins and Plant Lectins as Tools for Studies in Neurosciences, 2020, 18, 1570159X, 202, 10.2174/1570159X17666191016092221 | |
| 2. | Mehmet Burak Yalçın, Ejder Saylav Bora, Oytun Erbaş, The Effect of Liraglutide on Axon Regeneration and Functional Recovery after Peripheral Nerve Lesion, 2024, 46, 1467-3045, 327, 10.3390/cimb46010021 |
Figures(4)
Shizuka Takaku, Naoko Niimi, Toshihiko Kadoya, Hideji Yako, Masami Tsukamoto, Kunihiko Sakumi, Yusaku Nakabeppu, Hidenori Horie, Kazunori Sango. Galectin-1 and galectin-3 as key molecules for peripheral nerve degeneration and regeneration[J]. AIMS Molecular Science, 2016, 3(3): 325-337. doi: 10.3934/molsci.2016.3.325
DownLoad: 